Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma
| Autor: | Garrett Lasalle, Howard J. Landy, Angela Marini, Isildinha M. Reis, Priscilla Potter, Arnold M. Markoe, Niramol Savaraj, Lynn G. Feun, Deborah Heros, Medhi Wangpaichitr |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Radiation-Sensitizing Agents medicine.medical_treatment Deep vein Urology Brain tumor Pilot Projects Radiosurgery Glioma Medicine Humans Aged Radiotherapy business.industry Brain Neoplasms Middle Aged medicine.disease Combined Modality Therapy Magnetic Resonance Imaging Survival Analysis Clinical trial Radiation therapy medicine.anatomical_structure Treatment Outcome Neurology Oncology Estramustine Female Neurology (clinical) business Nuclear medicine medicine.drug Anaplastic astrocytoma |
| Zdroj: | Journal of neuro-oncology. 67(1-2) |
| ISSN: | 0167-594X |
| Popis: | Patients with high grade glioma generally have poor prognoses. Addition of radiosensitizing agents might improve the response to irradiation. The chemotherapeutic agent estramustine sensitizes experimental gliomas to radiation. Gliomas express estramustine binding proteins, and cytotoxic concentrations of estramustine metabolites are found in gliomas after oral administration. Twenty three patients, aged 25-78, with new or recurrent high grade glioma were treated with estramustine and radiosurgery and/or radiotherapy. Patients with recurrent tumors were treated with estramustine and Gamma Knife stereotactic radiosurgery; eligible tumors were limited to 4 cm maximal diameter. Patients with newly diagnosed tumors were treated with estramustine and fractionated radiotherapy, with radiosurgery also performed if the tumor was less than 4 cm maximal diameter. Estramustine (16 mg/kg per day orally) was started three days prior to radiosurgery, or, if only radiotherapy was performed, on the first day of radiotherapy. Estramustine was continued until the completion of radiosurgery and/or radiotherapy (72 Gy, 60 fractions, 1.2 Gy bid over 6 weeks). Of the 13 patients treated for newly diagnosed glioblastoma, median survival was 16 months with 38% 2-year survival. Of five patients treated for recurrent glioblastoma, survival was 3, 8, 9, 15, and 23 + months. Two patients with recurrent anaplastic astrocytoma survived for 24 and 48+ months. One patient with recurrent anaplastic mixed glioma survived 5+ months. Two patients with newly diagnosed anaplastic oligodendroglioma survived 20 and 42+ months. Four of the new glioblastoma patients developed deep vein thrombosis. The results of this pilot study indicate some benefit, and further investigation incorporating estramustine into clinical trials is suggested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink